Related Experiment Video
Updated: Dec 26, 2025

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
GOAL Canada: Physician Education and Support Can Improve Patient Management
Anatoly Langer1, Mary Tan1, Shaun G Goodman1,2
1Canadian Heart Research Centre, North York, Ontario, Canada.
Optimizing lipid-lowering therapy in Canadian patients with cardiovascular disease significantly increased achievement of low-density lipoprotein cholesterol (LDL-C) goals. This real-world study highlights the feasibility of guideline-directed management for reducing cardiovascular risk.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Many Canadian patients with cardiovascular disease (CVD) fail to reach recommended low-density lipoprotein cholesterol (LDL-C) levels despite statin use.
- Approximately 40-50% of Canadian patients with known CVD do not achieve their LDL-C goal.
- The Guidelines Oriented Approach to Lipid lowering (GOAL) study investigated real-world secondary and third-line lipid-lowering therapy.
Purpose of the Study:
- To assess the impact of second- and third-line lipid-lowering therapies on LDL-C goal achievement in a real-world Canadian setting.
- To evaluate the effectiveness of guideline-oriented management in patients with clinical vascular disease or familial hypercholesterolemia.
Main Methods:
- The GOAL study enrolled 2009 patients with CVD or familial hypercholesterolemia and LDL-C > 2.0 mmol/L despite maximally tolerated statin therapy.
- Physicians managed patients with online reminders of guideline recommendations during follow-up.
- Baseline lipid levels and therapies were recorded, and LDL-C goal achievement (< 2.0 mmol/L) was assessed.
Main Results:
- 50.8% of patients achieved the target LDL-C level (< 2.0 mmol/L) following the introduction of additional lipid-lowering therapies.
- Patients achieving LDL-C goals were more likely to be not statin intolerant and to receive high-efficacy statin therapy.
- Key reasons for not using ezetimibe included patient refusal (33%) and perceived lack of need (22%); for PCSK9 inhibitors, cost (26%) and patient refusal (25%) were primary barriers.
Conclusions:
- Optimizing lipid-lowering management is feasible and leads to achievement of guideline-recommended LDL-C levels in Canadian patients.
- Improved LDL-C control has the potential to significantly reduce cardiovascular morbidity and mortality in this population.
- Addressing barriers such as patient refusal, cost, and perceived need is crucial for effective lipid management.
Related Concept Videos
Patient-centered Care
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...
Acute Coronary Syndrome IV: Interprofessional Care
Introduction To Health Care Delivery System
The Institute of Medicine (IOM) advocates for a patient-centered, effective, safe, timely, equitable, and effective healthcare system. The National Priorities...
Peripheral Artery Disease III: Interprofessional Care
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation

